Scarica l'app Stockscreener
29.85
0.03%
-0.010
Dopo l'orario di chiusura:
28.65
-1.20
-4.02%
Precedente Chiudi:
$29.86
Aprire:
$29.95
Volume 24 ore:
885.49K
Relative Volume:
1.03
Capitalizzazione di mercato:
$3.43B
Reddito:
$22.50M
Utile/perdita netta:
$-203.82M
Rapporto P/E:
-17.09
EPS:
-1.7469
Flusso di cassa netto:
$-148.03M
1 W Prestazione:
+3.93%
1M Prestazione:
-9.52%
6M Prestazione:
-21.70%
1 anno Prestazione:
+47.48%
Intervallo 1D:
$29.10
$31.00
Intervallo di 1 settimana:
$27.93
$31.00
Portata 52W:
$16.79
$42.00
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Nome
Newamsterdam Pharma Company Nv
Settore
Industria
Telefono
35 206 2971
Indirizzo
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
29.85 | 3.43B | 22.50M | -203.82M | -148.03M | -1.7469 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Iniziato | Truist | Buy |
| 2025-10-20 | Ripresa | H.C. Wainwright | Buy |
| 2025-08-25 | Iniziato | Wells Fargo | Overweight |
| 2025-07-17 | Iniziato | Goldman | Neutral |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2025-06-10 | Iniziato | Stifel | Buy |
| 2025-06-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-15 | Iniziato | TD Cowen | Buy |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-18 | Iniziato | Guggenheim | Buy |
| 2024-01-16 | Iniziato | Piper Sandler | Overweight |
| 2023-10-30 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Newamsterdam Pharma Company Nv Borsa (NAMS) Ultime notizie
(NAMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Five new hires at NewAmsterdam get stock awards covering 65,800 shares - Stock Titan
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Pictet Asset Management Holding SA Lowers Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Jennison Associates LLC Trims Stock Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
What sustainable investing NewAmsterdam (NAMSW)? (+5.61%) 2026-04-29Community Watchlist - Newser
143,549 Shares in NewAmsterdam Pharma Company N.V. $NAMS Bought by Moody Aldrich Partners LLC - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 8%What's Next? - MarketBeat
NAMSW Price History for Newamsterdam Pharma Company N.V. WT Stock - Barchart.com
Understanding Momentum Shifts in (NAMSW) - Stock Traders Daily
NewAmsterdam Pharma Company N.V. Files 8-K with SEC: Company Information, NASDAQ Listing, and Key Filing Details - Minichart
NewAmsterdam Pharma Announces Chief Accounting Officer Transition Agreement - TipRanks
NewAmsterdam Pharma (NAMS) details CAO exit, bonus and equity terms - Stock Titan
NAMS (NewAmsterdam Pharma Company N.V. Ordinary Shares) reports wider-than-expected Q4 2025 losses, stock dips 1.25% as revenue halves year-over-year.Most Discussed Stocks - Xã Thanh Hà
NewAmsterdam Pharma Co. NV Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
NAMS (NewAmsterdam Pharma Company N.V. Ordinary Shares) posts wider than expected Q4 2025 loss, shares rise 4.46 percent on upbeat investor sentiment.Social Momentum Signals - Cổng thông tin điện tử tỉnh Tây Ninh
NAMSW (NewAmsterdam) does not disclose core quarterly earnings metrics as investors await further operational guidance details.Growth Pick - Cổng thông tin điện tử tỉnh Tây Ninh
Price-Driven Insight from (NAMS) for Rule-Based Strategy - Stock Traders Daily
What is limiting NewAmsterdam (NAMS) stock performance (Breakout Watch) 2026-04-20Community Risk Signals - Xã Thanh Hà
NewAmsterdam Pharma (NAMS) AGM June 2, 2026: ESPP, auditors, director votes - Stock Titan
Avoiding Lag: Real-Time Signals in (NAMSW) Movement - Stock Traders Daily
NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today (NASDAQ:NAMS) - Seeking Alpha
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Resistance Check: What are the risks of holding NewAmsterdam Pharma Company NV Equity WarrantQuarterly Trade Review & Real-Time Buy Zone Alerts - baoquankhu1.vn
NewAmsterdam Pharma Company (NAMS): Huge upside potential grabs attention of billionaire Stan Druckenmiller - MSN
Pullback Watch: What are the risks of holding NewAmsterdam Pharma Company NV Equity Warrant2026 Fed Impact & Weekly Return Optimization Plans - baoquankhu1.vn
(NAMS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Published on: 2026-04-11 17:21:30 - baoquankhu1.vn
NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference - Sahm
A Look At NewAmsterdam Pharma (NAMS) Valuation As Hedge Funds Focus On Obicetrapib’s Phase 3 LDL C Results - Yahoo Finance
NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan Druckenmiller - Insider Monkey
Gains Report: Will NewAmsterdam Pharma Company NV Equity Warrant benefit from AI trendsEntry Point & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Does NewAmsterdam Pharma (NAMS) CETP Optimism Point To A Durable Edge In Cardiovascular Treatment? - Sahm
Short Squeeze: Will NewAmsterdam Pharma Company NV stock recover after earnings2026 Retail Activity & Weekly High Return Forecasts - baoquankhu1.vn
Billionaire Stan Druckenmiller’s 5 Small and Mid-Cap Stock Picks with Huge Upside Potential - Insider Monkey
Is NewAmsterdam (NAMSW) Stock Attractive Now | Price at $23.71, Up 12.53%Expert Momentum Signals - Xã Châu Thành
Aberdeen Group plc Has $25.59 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Is NewAmsterdam (NAMS) Stock a Good Buy in 2026 | Price at $33.00, Up 0.03%Social Buy Zones - Xã Vĩnh Công
Discipline and Rules-Based Execution in NAMSW Response - Stock Traders Daily
Will NewAmsterdam Pharma Company NV benefit from seasonality2026 Key Highlights & Trade Opportunity Analysis - baoquankhu1.vn
NAMS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NAMS Stock Analysis: NewAmsterdam Pharma 0.55 pct daily gain 32.99 price outlook - UBND thành phố Hải Phòng
Two new hires get 15,000 stock options and 3,200 RSUs at NewAmsterdam - Stock Titan
Here’s Why NewAmsterdam Pharma Company N.V. (NAMS) Surged 23% in Q4 - Insider Monkey
NAMSW SEC FilingsNewAmsterdam Pha 10-K, 10-Q, 8-K Forms - Stock Titan
Pullback Watch: Is NewAmsterdam Pharma Company NV Equity Warrant stock trending bullish2026 Buyback Activity & Daily Technical Forecast Reports - baoquankhu1.vn
(NAMS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Revenue Check: Does NewAmsterdam Pharma Company NV have declining or rising EPSWeekly Gains Summary & Safe Entry Trade Reports - baoquankhu1.vn
Will ACC.26 Obicetrapib Data on Kidney, Safety and Lipids Change NewAmsterdam Pharma's (NAMS) Narrative? - Sahm
Newamsterdam Pharma Company Nv Azioni (NAMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):